Company Overview and News

0
Torrent Power Limited - Updates

2018-07-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TORNTPOWER 532779

0
Torrent Power Limited - Trading Window

2018-06-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TORNTPOWER 532779

38
Market Live: Nifty at day#39;s high, Sensex jumps 300 pts; Europe trades strong

2018-06-29 moneycontrol
The rupee has been one of the worst performing currencies among peers. Against the USD, it has depreciated by 6.6 percent in calendar year 2018 and 8 percent, Year to Date (YTD). Adding to our concern is the increasingly hawkish Federal Reserve, which has now initiated a reversal of the Quantitative Easing (QE) – marking an end to global easy money.
BAJAJ-AUTO INDIANB 500325 IDRNF 500207 TCHQY 532712 532755 534976 5225 RCOM TORNTPOWER 522287 LHFLY 500570 500253 SUNTV RLNIY SBAZ BANG GRAPHITE 532946 JSWSTEEL TECHM TATASTEEL FORTIS TATLY LICHSGFIN Q0F 500228 RELIANCE 532814 532779 532977 532733 500470 RIGD IHHHF TATAMOTORS 509488 INDIGO HINDALCO IBN 532843 539448 HNDNF VMART ICICIBANK TTST 532174 KALPATPOWR SNQVY 500440 INDORAMA TTM

29
Market Live: Sensex extends gains, Nifty inches towards 10,700; ICICI Bank in focus

2018-06-29 moneycontrol
ICICI Bank extends gains: The country's largest private sector lender informed exchanges that the board of directors appointed Girish Chandra Chaturvedi as an additional (Independent) director effective July 1, 2018 for a period of 3 years subject to the approval of shareholders as the term of office of M K Sharma expires on June 30, 2018.
BAJAJ-AUTO INDIANB 500325 500228 IDRNF 500207 RELIANCE 532814 TCHQY 532779 532977 532755 532733 534976 500470 RIGD TORNTPOWER 522287 LHFLY 500570 TATAMOTORS 509488 500253 SUNTV RLNIY INDIGO HINDALCO BANG GRAPHITE IBN 532946 JSWSTEEL TECHM 539448 HNDNF VMART ICICIBANK TTST TATASTEEL TATLY LICHSGFIN 532174 KALPATPOWR SNQVY 500440 INDORAMA TTM

0
Torrent Power Limited - Book Closure

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TORNTPOWER 532779

0
Torrent Power Limited - Reply to Clarification Sought

2018-06-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TORNTPOWER 532779

28
Closing Bell: Sensex up 416 pts, Nifty ends May series above 10,700; HDFC Bank leads

2018-05-31 moneycontrol
Fundraising: Multiplex operator PVR is evaluating acquisition opportunities of cinema exhibition chains and plans to raise funds to carry out the transaction through issuance of non convertible debentures (NCDs).
IOC SUZLON ARCHIDPLY CAPF TCHQY 532755 532710 532400 KPIT TORNTPOWER 500570 SUEL CLNDY EVSJF 530965 532667 TECHM 532994 500182 500180 520051 KOTAKBANK 534809 PCJEWELLER COALINDIA HINDCOPPER 532938 532779 533278 532541 532187 HDFCBANK HEROMOTOCO SADBHAV TATAMOTORS NIITTECH ESI INDUSINDBK KMBKY IBN 513599 539207 ICICIBANK HDB 532174 JAMNAAUTO HRTQY 500247 MANPASAND TTM

0
Torrent Power Limited - Clarification

2018-05-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TORNTPOWER 532779

0
Torrent Power (₹254.1): Buy

2018-05-30 premium.thehindubusinessline
Yoganand D Investors with a short-term perspective can buy the stock of Torrent Power at current levels. The stock has been in a near-term rally since taking support at ₹214, over the past five trading sessions. The stock gained almost 5 per cent on Wednesday, breaching a key resistance as well as 200-day moving average at ₹250 levels, thereby strengthening the current up move.
TORNTPOWER 532779

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...